Author name: Ananta Kar

Ananta is wrapping up her postgraduate studies in Comparative Literature whilst juggling a solid two-year writing career. She cut her teeth as a sports journalist before discovering her true passion: India's exploding gaming scene. These days, she's obsessed with how gaming culture is reshaping the country, and her academic research chops bring unexpected depth to every piece. Whether dissecting esports trends or exploring biologics in India, renewable energy, electric Vehicles & Smart Transportation topics, Ananta writes with the curiosity of a researcher and the energy of someone who genuinely loves what they do.

Avatar photo

Budget 2026’s Green Gamble: Why Indian Buyers Are Choosing Hybrids Over the Ev Future

There is a revealing irony at the heart of India’s clean mobility push. The government has committed ₹10,000 crore under FAME-III, launched a ₹11,000 crore PM E-Drive Scheme, and staked the credibility of its Viksit Bharat narrative on electric vehicles — and yet consumer surveys consistently show that only 5% of prospective buyers intend to […]

Budget 2026’s Green Gamble: Why Indian Buyers Are Choosing Hybrids Over the Ev Future Read More »

Budget 2026’s Defining Test: Will India Let a ₹20,000 Gap Kill Its Electric Future?

India’s electric vehicle revolution has a fundamental problem, and it has nothing to do with technology. The batteries are improving, the designs are maturing, and the policy intent is genuinely ambitious. Yet for the daily commuter in Bareilly or the smallholder farmer eyeing a two-wheeler in rural Bihar, the arithmetic simply does not add up.

Budget 2026’s Defining Test: Will India Let a ₹20,000 Gap Kill Its Electric Future? Read More »

Budget 2026’s Make-or-Break Moment: Can India Fix Its Ev After-Sales Crisis Before It’s Too Late?

India’s electric vehicle ambitions are colliding headlong with a crisis that no amount of subsidy can paper over. With the government eyeing 30% EV penetration by 2030 and FAME-III committing ₹10,000 crore to accelerate adoption, the uncomfortable truth is that the after-sales ecosystem — the unglamorous backbone of any automotive market — remains dangerously underdeveloped.

Budget 2026’s Make-or-Break Moment: Can India Fix Its Ev After-Sales Crisis Before It’s Too Late? Read More »

India’s Electric Dream Meets Power Nightmare: 100 TWh Grid Shock Looms by 2030

Your electric car charges overnight whilst you sleep. So do your neighbour’s. And the entire apartment complex’s. And every vehicle across Delhi-NCR simultaneously drawing power from a grid already stretched to capacity. India’s electric vehicle revolution targeting 30 per cent market penetration by 2030 faces a stark infrastructure reality: charging demand could surge by 100

India’s Electric Dream Meets Power Nightmare: 100 TWh Grid Shock Looms by 2030 Read More »

Brazil to India: Stop Selling Us Drugs, Help Us Make Them Instead

Brazil imports billions worth of medicines from India annually. Now, Health Minister Alexandre Padilha wants to fundamentally rewrite that relationship. Rather than merely purchasing finished generics and active pharmaceutical ingredients from Indian manufacturers, Brazil seeks strategic partnerships to establish local production facilities, transfer technology, and build genuine pharmaceutical manufacturing capacity within Brazilian borders. This dramatic

Brazil to India: Stop Selling Us Drugs, Help Us Make Them Instead Read More »

AI Meets Biologics: How India Plans to Reinvent Itself Beyond Generic Drugs

What takes ten years and costs $2 billion? Until recently, developing a single new drug molecule. What now takes months and costs a fraction of that? The same process powered by artificial intelligence platforms that Hyderabad‘s Genome Valley startups are wielding to transform India from the world’s pharmacy into a genuine innovation hub. At BioAsia

AI Meets Biologics: How India Plans to Reinvent Itself Beyond Generic Drugs Read More »

From 2% to Superpower: India’s Nutraceutical Sector Eyes Its $65 Billion Moment

India controls just 2 percent of the $400 billion global nutraceutical market. Yet FSSAI officials project the sector will outpace pharmaceuticals by tenfold—a claim that would sound audacious were it not grounded in converging forces rarely seen simultaneously in a single industry. Post-pandemic health consciousness has permanently shifted consumer behaviour away from reactive medicine towards

From 2% to Superpower: India’s Nutraceutical Sector Eyes Its $65 Billion Moment Read More »

India Could Halve Transport Emissions by 2050—if Its Ev Targets Hold

Road transport accounts for 56 per cent of India’s sectoral carbon dioxide emissions. If India achieves its declared electric vehicle targets, that figure could be cut in half by 2050—delivering one of the largest absolute emissions reductions of any nation on earth. The International Council on Clean Transportation’s Vision 2050 analysis, released on 16th February

India Could Halve Transport Emissions by 2050—if Its Ev Targets Hold Read More »

Global Ev Sales Crash 3%: China’s Tax Shock and Trump’s Reversal Halt Revolution

The global electric vehicle revolution just hit its first speed bump. After years of relentless growth that saw manufacturers commit hundreds of billions to electrification, global electric vehicle registrations—a reliable proxy for sales—contracted 3% year-on-year to 1.2 million units in January 2026 according to Benchmark Mineral Intelligence data, hammered by China‘s new purchase tax and

Global Ev Sales Crash 3%: China’s Tax Shock and Trump’s Reversal Halt Revolution Read More »

The Pioneer Who Proved India Could Innovate: Ranjan Chakrabarti’s Journey From Us Consulate Reader to Biopharma Trailblazer

In the mid-1990s, suggesting that India could venture into original drug discovery research wasn’t just optimistic—it was laughable. The country’s pharmaceutical prowess rested entirely on reverse-engineering Western patents, manufacturing generics cheaply, and exporting to developing markets. Innovation? New chemical entities? Clinical trials meeting US FDA standards? These belonged to multinational pharmaceutical giants operating from gleaming

The Pioneer Who Proved India Could Innovate: Ranjan Chakrabarti’s Journey From Us Consulate Reader to Biopharma Trailblazer Read More »

Scroll to Top